For more information or confidential assistance
se habla español

Study Suggests Xarelto Presents Greater Risk for Kidney Patients

According to recently-released research findings, next-generation blood-thinning drug Xarelto may pose additional risk to patients who are already suffering from kidney disease. The study, based on data taken from the Department of Defense electronic medical records system, found that those with existing kidney ailments were significantly more likely to experience... Read more »

Several Claims Added to Xarelto MDL

On December 2, 2015, six additional claimants added their causes of action to the pending multidistrict litigation (MDL) involving the blood-thinning drug Xarelto. Xarelto, which is also known rivaroxaban, is a relatively new blood thinning drug touted to offer patients an increased level of convenience as they treat their underlying... Read more »

Status Conference Scheduled for GranuFlo, NaturaLyte MDL

The parties involved in the GranuFlo and NaturaLyte multidistrict litigation were scheduled to meet on Friday, Nov. 22. In a status conference before U.S. District Judge Douglas P. Woodlock, both parties were expected to evaluate the proposed start dates for the first two bellwether trials, to see if they’re on-track. The... Read more »

Hundreds of Yaz Lawsuits Resolved with Settlements

Bayer Healthcare Pharmaceuticals has reported substantial progress during the latest status conference for the multidistrict litigation (MDL) No. 2100 regarding Yaz and Yasmin lawsuits. The status conference took place early in November 2015. It was presided over by U.S. District Judge David R. Herndon of the Southern District of Illinois.... Read more »

Androgel Lawsuits Identified for Bellwether Trial Pool

The first bellwether trials in multidistrict litigation 2545, which concerns injuries allegedly caused by testosterone replacement therapy, are slated to go to trial by fall of 2016. Court dockets show that more than 2,700 complaints are currently pending against the manufacturers of Testim, Adroderm, Androgel, Axiron and other products that... Read more »

Zofran Lawsuits Consolidated Under Multidistrict Litigation

The U.S. Judicial Panel on Multidistrict Litigation (JPML) issued a transfer order on October 13, 2015 to centralize all federal Zofran claims into a multidistrict litigation (MDL). The MDL is pending in the U.S. District Court for the District of Massachusetts, where it is proceeding under the direction of Judge F.... Read more »